Explore the latest developments showcased at World ADC, highlighting smarter payloads and precise targeting in drug discovery.

Explore the World ADC Conference highlights on antibody-drug conjugates and their impact on cancer therapy and clinical ...

Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu ® Clinical trial with AVA6103 is expected to be initiated ...

BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical data ...

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...

What are the biggest hurdles preventing the wider adoption/utilization of ADCs? Stability and toxicity are two of the major challenges. First, linker stability issues result in the immediate release ...

Avacta's preCision platform is a proprietary payload delivery system designed to concentrate highly potent payloads in the tumour microenvironment while sparing normal tissues.

LONDON and PHILADELPHIA - February 24, 2026 - Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology ...

Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu® LONDON and PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) - ...